The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: A systematic review

被引:29
|
作者
Jassem, Jacek [2 ]
Carroll, Christopher [1 ]
Ward, Sue E. [1 ]
Simpson, Emma [1 ]
Hind, Daniel [1 ]
机构
[1] Univ Sheffield, ScHARR, Sheffield, S Yorkshire, England
[2] Med Univ Gdansk, Dept Radiotherapy & Oncol, Gdansk, Poland
关键词
Review; Breast neoplasms; Neoplasms metastes; Anthracyclines; Taxoids; Survival; Adult; Female; Quality of life; PHASE-III TRIAL; CHEMOTHERAPY; VINORELBINE; SURVIVAL; METAANALYSES; CAPECITABINE; QUALITY;
D O I
10.1016/j.ejca.2009.05.035
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Currently available evidence does not provide definitive guidance regarding the optimal chemotherapy agents and combinations in anthracycline- and taxane-pretreated advanced breast cancer. We performed a systematic review of controlled clinical trials of the cytotoxic agents currently used for this population in Europe: capecitabine, gemcitabine, vinorelbine, docetaxel, paclitaxel and paclitaxel protein-bound particles. Method: A systematic review of randomised (RCT) and non-randomised controlled clinical trials (non-RCTs). The primary outcomes of interest were overall survival (OS) and progression-free survival (PFS); secondary outcomes were duration of response (DR), overall response rate (ORR), adverse events and quality of life (QoL). Six electronic databases and grey literature sources were searched; reference tracking was performed on included publications. A narrative synthesis was conducted: heterogeneity of study design and interventions prevented meta-analysis. Results: No randomised controlled trial (RCT) found any significant differences between any of the regimens in terms of OS. In terms of PFS, only gemcitabine plus vinorelbine performed significantly better than its comparator, vinorelbine alone. For secondary outcomes, only capecitabine plus bevacizumab had a significantly better outcome than its comparator, capecitabine alone, in terms of ORR. A low quality non-RCT found that both capecitabine monotherapy and a combination of capecitabine plus vinorelbine were significantly more effective than vinorelbine alone in terms of OS and ORR. Across all trials, median OS for these patients typically remained less than 16 months. Conclusion: The quantity and quality of the available evidence regarding the efficacy of the particular chemotherapy regimens in patients with advanced breast cancer pre-treated with an anthracycline and a taxane is extremely limited. New effective therapies are sorely needed in this population. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2749 / 2758
页数:10
相关论文
共 50 条
  • [1] Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer
    Pugliano, Lina
    de Azambuja, Evandro
    ONKOLOGIE, 2012, 35 (09): : 476 - 478
  • [2] Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer
    Wist, EA
    Sommer, HH
    Ostenstad, B
    Risberg, T
    Bremnes, Y
    Mjaaland, I
    ACTA ONCOLOGICA, 2004, 43 (02) : 186 - 189
  • [3] Chemotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer: An overview
    Andreopoulou E.
    Sparano J.A.
    Current Breast Cancer Reports, 2013, 5 (1) : 42 - 50
  • [4] Potential role of pemetrexed in metastatic breast cancer patients pretreated with anthracycline or taxane
    Zhou Li-Yan
    Shi Ye-Hui
    Jia Yong-Sheng
    Tong Zhong-Sheng
    慢性疾病与转化医学(英文), 2015, 1 (01) : 27 - 28-29-30-31-32-33-34-35
  • [5] High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer
    V. Heinemann
    H. J. Stemmler
    A. Wohlrab
    D. Bosse
    C. Losem
    S. Kahlert
    G. Rauthe
    Cancer Chemotherapy and Pharmacology, 2006, 57 : 640 - 646
  • [6] High efficacy of gemcitabine and cisplatin in patients with predominantly anthracycline- and taxane-pretreated metastatic breast cancer
    Heinemann, V
    Stemmler, HJ
    Wohlrab, A
    Bosse, D
    Losem, C
    Kahlert, S
    Rauthe, G
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 57 (05) : 640 - 646
  • [7] Capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Lee, SH
    Lee, J
    Park, J
    Park, SH
    Lee, KE
    Lee, SI
    Nam, E
    Park, JO
    Kim, K
    Jung, CW
    Park, YS
    Yoon, SS
    Kang, WK
    Lee, MH
    Park, K
    Im, YH
    MEDICAL ONCOLOGY, 2004, 21 (03) : 223 - 231
  • [8] Capecitabine monotherapy in patients with anthracycline-and taxane-pretreated metastatic breast cancer
    S.-H. Lee
    J. Lee
    J. Park
    S. H. Park
    K.-E. Lee
    S. I. Lee
    E. Nam
    J. O. Park
    K. Kim
    C. W. Jung
    Y. S. Park
    S. S. Yoon
    W. K. Kang
    M. H. Lee
    K. Park
    Y.-H. Im
    Medical Oncology, 2004, 21 : 223 - 231
  • [9] Treatment strategies for patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Seidman, Andrew D.
    SEMINARS IN ONCOLOGY, 2008, 35 (02) : A3 - A4
  • [10] Efficacy and safety of ixabepilone plus capecitabine in elderly patients with anthracycline- and taxane-pretreated metastatic breast cancer
    Vahdat, Linda T.
    Vrdoljak, Eduard
    Gomez, Henry
    Li, Rubi Khaw
    Bosserman, Linda
    Sparano, Joseph A.
    Baselga, Jose
    Mukhopadhyay, Pralay
    Valero, Vicente
    JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (04) : 346 - 352